Immuno-Oncology Program Metrics

View the clinical trials, grants and publications from the Cancer Epidemiology Program.

Clinical Trials
CLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); FK506 (Tacrolimus); Melphalan (); Pacritinib (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus (); busulfan (); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 19337
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition: Breast
Intervention: DC1 Vaccine (); Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab (); Taxotere (docetaxel); Trastuzumab (); carboplatin (); docetaxel (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 19377
A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease
Condition: Malignant Hematology
Intervention: AMG 592 ()

CLINICAL TRIAL 19414
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)

CLINICAL TRIAL 19487
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); azacitidine (5-azacitidine)

CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011 (); BMS-936558 (Nivolumab); Nivolumab (Opdivo)

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 19837
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients with Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: IL-2 (Interleukin-2); MESNA (); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20082
Pilot Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2 Mutation
Condition: Malignant Hematology
Intervention: Enasidenib ()

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Varlilumab ()

CLINICAL TRIAL 19961
A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Condition: Malignant Hematology
Intervention: EQ001 (); Placebo ()

CLINICAL TRIAL 19960
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic Car T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma
Condition: Malignant Hematology
Intervention: ALLO-501 (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20042
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); G-CSF (); Idarubicin (); Zevados (Idarubicin); daunorubicin ()

CLINICAL TRIAL 20126
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20131
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); G-CSF (); Melphalan (); Mycophenolate Mofetil (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20132
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Condition: Multiple
Intervention: FLX475 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20163
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non©\Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature©\driven Analysis
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MK-3475 (Keytruda); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 20173
A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); IPI-549 (); Nab-paclitaxel (Abraxane)

CLINICAL TRIAL 20251
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 Study)
Condition: Immunotherapy
Intervention: ADP-A2M4 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20253
Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: CT053 ()

CLINICAL TRIAL 20274
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Radiotherapy (); cisplatin ()

CLINICAL TRIAL 20306
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Condition: Head & Neck
Intervention: Rivoceranib ()

CLINICAL TRIAL 20315
Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Tavo-EP ()

CLINICAL TRIAL 20377
A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors
Condition: Genitourinary
Intervention: ADT (); BMS-936558 (Nivolumab); Firmagon (); Lupron (leuprolide acetate); Nivolumab (Opdivo); Taxotere (docetaxel); Zoladex (); docetaxel (); goserelin acetate (Zoladex)

CLINICAL TRIAL 20484
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: MT-401 ()

CLINICAL TRIAL 20397
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Condition: Immunotherapy
Intervention: Itacitinib ()

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20533
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
Condition: Multiple
Intervention: ONCR-177 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Condition: Malignant Hematology
Intervention: ALLO-501A (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20557
A Phase II, Open-Label, Multicenter, Randomized Study of Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 20575
A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); CG0070 (); DDM (); Nivolumab (Opdivo)

CLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Condition: Immunotherapy
Intervention: CD19 CAR T Cells (); PCV13 ()

CLINICAL TRIAL 20614
A Phase III, Multicneter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib versus Cabozantinib Alone in Patients with Inoperable, Locally, Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Cabozantinib (XL 184)

CLINICAL TRIAL 20711
A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Condition: Genitourinary
Intervention: CG0070 (); DDM (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20712
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV- Associated Solid Tumors, with Expansion Cohorts in HIV-Associated Solid tumors and a Cohort of HIV- Associated Classical Hodgkin Lymphoma
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 20720
S1827, MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20722
Phase III Randomized Trial of Pleurectomy/Decortication plus Chemotherapy with or without Adjuvant Hemithoracic Intenstiy-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20730
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Condition: Breast
Intervention: Trastuzumab emtansine (); Tucatinib ()

CLINICAL TRIAL 20837
Envasarc: A Pivitol Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy
Condition: Sarcoma
Intervention: Envafolimab (); Ipilimumab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 20839
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo)

CLINICAL TRIAL 20939
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Binimetinib (); Encorafenib (); PF-06801591 (Sasanlimab); Sasanlimab ()

CLINICAL TRIAL 21029
A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pre-treated Subjects with Angiosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Nivolumab (Opdivo); Taxol (paclitaxel); paclitaxel ()

CLINICAL TRIAL 21214
Association of Gender with Adverse Events, Prescribing Patterns and Oncologic outcomes in Patients being treated with Immuno-Oncology Agents
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 50399
Mechanisms of Functional Heterogeneity of Tumor Associated Macrophages in Glioblastoma
Condition: Neurologic Oncology
Intervention:

Grants
  • Core Clinical Centers for Blood and Marrow Transplant Clincial Trials Network
    Sponsor: Nat Institutes of Health
    PI:Pidala, J.
  • The National Myelodysplastic Syndromes Natural History Study (The National MDS Study) - Central Laband Biorepository
    Sponsor: Nat Institutes of Health
    PI:Burnette, P.
  • Defining the Transplantation Tolerance Transcriptome: A Path Toward Individualized Management of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation
    Sponsor: Nat Marrow Donor Program
    PI:Pidala, J.
  • Correcting the Anti-HER-2 CD4 Th1 Response in Breast Cancer Therapy to Prevent Recurrence
    Sponsor: US Army
    PI:Czerniecki, B.,CO-PI:Soliman, H.
  • Tumor Infiltrating Lymphocyte Adoptive T Cell Therapy for NSCLC
    Sponsor: Stand Up To Cancer
    PI:Haura, E.
  • Targeting Immunosuppressive Cancer Associated Fibroblasts and Immune Checkpoints in NSCLC
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Gray, J.
  • Augmenting T Cell Trafficking and Functionality through Novel Combinations of Epigenetic Agents and PD-1 Blockade
    Sponsor: Nat Institutes of Health
    PI:Beg, A.
  • Global Control of Ovarian Cancer Immunity by Aberrant ER Stress Responses
    Sponsor: Cornell University
    PI:Conejo-Garcia, J.
  • Pediatric Clinical Research - Cutaneous
    Sponsor: V Fdtn for Cancer Research
    PI:Sondak, V.
  • Initiation and Evolution of the Ovarian Cancer Microenvironment-Transfer App
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Development of CAR-T/CER-T Therapies for Ovarian Cancer
    Sponsor: Certainty Therapeutics, Inc.
    PI:Conejo-Garcia, J.
  • Regulatory Dendritic Cells in Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Defining Impact of HDAC Inhibitors on Tumor Immunogenicity, T Cell Functionality and PD-1 Blockade Response in NSCLC Patients
    Sponsor: US Army
    PI:Beg, A.
  • Regulation of dendritic cell function and tumor immunity by TIM-3
    Sponsor: Nat Institutes of Health
    PI:Ruffell, B.
  • Study to Determine the Efficacy of the Protein X to Induce Acute Lymphoblastic Leukemia in Humanized Mice Model as Compared to Control
    Sponsor: 1 Voice Foundation
    PI:Sahakian, E.
  • B Cell-dependent Anti-tumor Immunity in Ovarian Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Rapid Exoproteome Antigen Profiling of antibodies produced in the ovarian cancer microenvironment
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Functional reprogramming of tumor-MDSC through antibody-based therapies Targeting Notch Ligands
    Sponsor: Nat Institutes of Health
    PI:Rodriguez, P.
  • Prescreening Strategies to Increase Clinical Trial Participation
    Sponsor: V Fdtn for Cancer Research
    PI:Soliman, H.
  • Gene Engineered T-Cell Therapy (AML)
    Sponsor: Atara Biotherapeutics, Inc.
    PI:Davila, M.
  • Gene Engineered T-Cell Therapy (Co-Stimulatory Domains)
    Sponsor: Atara Biotherapeutics, Inc.
    PI:Davila, M.
  • Development of T-Cells that target B-Cell Antigens
    Sponsor: Atara Biotherapeutics, Inc.
    PI:Davila, M.
  • Novel Immunotherapy for Brain-Metastatic Breast Cancer
    Sponsor: US Army
    PI:Czerniecki, B.
  • Targetable Epidgenetic Mechanism Driving Cutaneous T Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (Contact):Conejo-Garcia, J.,PI (MPI):Pinilla, J.,PI (MPI):Sokol, L.
  • Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
    Sponsor: Nat Institutes of Health
    PI:Abate Daga, D.
  • The impact of donor gamma delta T-cell reconstitution and expression of leukemic cell ligands on immune escape and relapse of AML after allogeneic hematopoietic cell transplantation
    Sponsor: Tampa Community Foundation
    PI:Bejanyan, N.
  • Donor gamma delta T-cell infusion for treatment of high-risk leukemia
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Bejanyan, N.
  • Promoting an Effective Immune Response in Lymphoma
    Sponsor: US Army
    PI:Lazaryan, A.
  • Phase I/II Study of CD8-Reduced T Cells for Treatment of Myelodysplastic Syndrome or Acute Myeloid Leukemia IND17305-(12/30/2016)
    Sponsor: US Food & Drug Administration
    PI:Elmariah, H.
  • FVIII TCR-Engineered T-Reg Cell Product
    Sponsor: Nat Institutes of Health
    PI:Landin, A.
  • Breast cancer immunotherapy with anti-TIM-3
    Sponsor: US Army
    PI:Ruffell, B.
  • Adrenergic modulation of cellular immune functions in CAR T cell–induced cytokine release syndrome
    Sponsor: Nat Institutes of Health
    PI:Davila, M.
  • Precision Interception of Aggressive Prostate Cancer In African American Men
    Sponsor: Nat Institutes of Health
    PI:Rounbehler, R.
  • Role of Sirt2 in T Cell Metabolism
    Sponsor: Nat Institutes of Health
    PI:Kim, S.
  • Ustekinumab for Graft vs Host Disease Prevention (IND 144540)
    Sponsor: US Food & Drug Administration
    PI (MPI):Pidala, J.
  • Exploiting the Immune Mapping of the Tumor Microenvironment to Improve Immunotherapy of Melanoma
    Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
    PI:Mulé, J.
  • Research Collaboration focused on cytokine analyses and immune phenotype/correlative analyses
    Sponsor: Precigen
    PI:Davila, M.
  • Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
    Sponsor: Incyte, Inc.
    PI:Pinilla, J.
  • Determine the effects of the TP-0184 and its derivatives (second generation) on myeloid-derived suppressor cell (MDSC)-mediated suppressive functions and improve the local bone marrow (BM) microenvironment in patients with MDS
    Sponsor: Tolero Pharmaceuticals
    PI (Contact):Wright, K.,PI:Eksioglu, E.
  • Intellia Research Collaboration - Project 1: Advancing Neoantigen-Specific T Cells
    Sponsor: Intellia Therapeutics
    PI:Pilon-Thomas, S.,CO-PI:Abate Daga, D.
  • A Phase II Biomarker Trial of CC-122 in Combination with Nivolumab in Advanced Melanoma
    Sponsor: Celgene Corp.
    PI:Pilon-Thomas, S.
  • Notch signaling boosts T cell-based immunotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Rodriguez, P.,CO-PI:Luca, V.
  • Clinical investigation to improve efficacy of CAR-T Cell Therapy for Large B Cell Lymphoma
    Sponsor: Leukemia & Lymphoma Society
    PI:Locke, F.
  • Compartmentalized and Systemic Interactions of the Skin Microbiome in Cancer Immunotherapy Response
    Sponsor: The Jackson Laboratory
    PI:Markowitz, J.
  • MIDAS: Microangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation
    Sponsor: Nat Institutes of Health
    PI:Bejanyan, N.
  • A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic Parameters, and Pharmacodynamics of TGR-1202 (Umbralisib) in Treatment Naïve Patients with Chronic Lymphocytic Leukemia (CLL)
    Sponsor: TG Therapeutics
    PI:Pinilla, J.
  • Correlative Studies for MCC 19197
    Sponsor: Bristol Myers Squibb Company
    PI:Brayer, J.
  • Immune Modulation by TIM-3
    Sponsor: Tesaro, Inc.
    PI:Ruffell, B.
  • Characterization of Evolving Immune Profiles of Marrow-Infiltrating Lymphocytes Engineered to Express a BCMA-Targeting Chimeric Antigen Receptor
    Sponsor: WindMIL Therapeutics
    PI:Brayer, J.
  • Myst – Moffitt Collaboration - Melanoma & Colorectal
    Sponsor: Myst Therapeutics
    PI (Contact):Pilon-Thomas, S.,CO-PI:Beatty, M.,CO-PI:Fleming, J.,CO-PI:Teer, J.,CO-PI:Mulé, J.
  • Efficacy and immune-profilking post treatment with ME-401
    Sponsor: MEI Pharma
    PI:Pinilla, J.
  • Companion Biomarker Study for the Phase II Randomized study of Nivolumab, Ipilimumab with or without Stereotactic Body Radiation Therapy in Metastatic or Recurrent Merkel Cell Carcinoma
    Sponsor: Bristol Myers Squibb Company
    PI:Kim, S.
  • Predictive Markers and Evolutionary Dynamics of Axicabtagene Ciloleucel in NHL patients
    Sponsor: Kite Pharma
    PI:Locke, F.
  • Severe ER stress limits the efficacy of promising CAR-T cell treatments
    Sponsor: Kite Pharma
    PI:Locke, F.
  • Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
    Sponsor: Nat Institutes of Health
    PI:Davila, M.
  • Role of anti-oncodriver Th1 immune response on disseminated cancer cells to prevent breast cancer metastasis
    Sponsor: Moffitt Cancer Center
    PI:Czerniecki, B.,CO-PI:Kodumudi, K.,CO-PI:Ramamoorthi, G.
  • Development of Expanded Access Criteria for Adoptive Cell Therapy in Soft Tissue Sarcoma
    Sponsor: Ocala Royal Dames
    PI:Mullinax, J.
  • Identification of biomarkers to predict the development of immune-related adverse events in patients treated with Tisagenlecleucel
    Sponsor: Novartis Pharmaceuticals Corp.
    PI:Davila, M.
  • Investigating the prognostic role of intrinsic immune evasion mechanisms in HNSCC
    Sponsor: Nat Institutes of Health
    PI:Wang, X.
  • Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy
    Sponsor: Nat Institutes of Health
    PI:Adeegbe, D.
  • NSG Mouse Models to Evaluate the Efficacy of TIL
    Sponsor: Iovance Biotherapeutics
    PI:Pilon-Thomas, S.
  • Role of Bcl11b in CD4+ T Cells and Innate Lymphoid Cells
    Sponsor: Nat Institutes of Health
    PI:Avram, D.
  • Tolerogenic Dual Microparticle System for Treatment of Multiple Sclerosis
    Sponsor: Nat Institutes of Health
    PI (MPI):Avram, D.
  • CD19 CAR-T Plus Elicio Amphiphile Combination Therapy
    Sponsor: Elicio Therapeutics
    PI:Davila, M.
  • High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase
    Sponsor: Nat Institutes of Health
    PI (MPI):Avram, D.
  • Altered Tumor-Immune Synapse in Merkel Cell Carcinoma Drives Immune Evasion
    Sponsor: Moffitt Cancer Center
    PI (Contact):Kim, S.
  • Overcoming Resistance in HER2 Breast Cancer through a Novel Immunotherapy Approach
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Czerniecki, B.
  • Validating and tailored targeting of identified immune signature in the tumors of African-American Prostate cancer patients
    Sponsor: Mike Slive Foundation
    PI:Adeegbe, D.
  • Study to develop a predictive model of immune-related adverse events in patients treated with axicabtagene ciloleucel
    Sponsor: Kite Pharma
    PI:Davila, M.,CO-PI:Faramand, R.
  • Identifying tumor-intrinsic resistance mechanisms in melanoma patients upon treatment with immunotherapy.
    Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
    PI:Hwu, P.
  • Implementation of a Tailored Mobile Application to Improve Clinical Trial Engagement in Breast Cancer Patients
    Sponsor: V Fdtn for Cancer Research
    PI:Soliman, H.,CO-PI:Armaghani, A.
  • Actionable cell stress mechanisms governing αb and gd T cell responses against ovarian cancer
    Sponsor: Moffitt Cancer Center
    PI (Contact):Conejo-Garcia, J.,CO-PI:Rodriguez, P.,CO-PI:Tworoger, S.
  • Developing an Oncolytic Virus to induce de novo T cell priming: impact on TIL generation and therapeutic efficacy
    Sponsor: Moffitt Cancer Center
    PI:Beg, A.
  • Role of Butyrophilins in Regulating T-Cell Activity
    Sponsor: Moffitt Cancer Center
    PI:Conejo-Garcia, J.
  • Mechanisms of functional heterogeneity of tumor associated macrophages in glioblastoma
    Sponsor: Ivy (Ben & Catherine) Fdtn
    PI:Veglia, F.
  • Exploratory and IND-enabling Preclinical Studies to Assess Pharmacology and Safety of Anti-BCMA γδ2 CAR-T cells Using In vitro and In vivo Models for the Treatment of Multiple Myeloma
    Sponsor: Bluebird Bio Inc
    PI (Contact):Abate Daga, D.
  • Feasibility Assessment and Design of Microbiota Collection Study from Patients Receiving Checkpoint Blockade
    Sponsor: Microba Pty Ltd - Australia
    PI:Markowitz, J.
  • Predictors of Immunotherapeutic Benefits in Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
    Sponsor: Tampa Community Foundation
    PI (Contact):Tarhini, A.
  • Preclinical studies of MEM-288
    Sponsor: Memgen
    PI:Beg, A.
Publications
  • Robinson LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, Bui MM, Druta M. Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas. J Thorac Cardiovasc Surg. 2021 Jul.162(1):274-284. Pubmedid: 32711968.
  • Britt J, Jain R, Li R. Robotic radical nephroureterectomy in a patient with situs inversus totalis. Urol Case Rep. 2021 Jul.37:101688. Pubmedid: 34040986. Pmcid: PMC8141754.
  • How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 Jul.162(1):24-31. Pubmedid: 33958211. Pmcid: PMC8222164.
  • Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, Tkaczyk E, Farhadfar N, Jain S, Stevens P, Luo ZK, Ogawa Y, Stern M, Yanik GA, Cuvelier GDE, Cheng GS, Holtan SG, Schultz KR, Martin PJ, Lee SJ, Pavletic SZ, Wolff D, Paczesny S, Blazar BR, Sarantopoulos S, Socie G, Greinix H, Cutler C. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplant Cell Ther. 2021 Jul.27(7):545-557. Pubmedid: 33839317.
  • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754.
  • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
  • Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith ES, Mishra V, Schröder A, Chin K, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul.27(13):3630-3640. Pubmedid: 33820783.
  • Yaghjyan L, Mai V, Wang X, Ukhanova M, Tagliamonte M, Martinez YC, Rich SN, Egan KM. Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women. Cancer Causes Control. 2021 Jul.32(7):681-692. Pubmedid: 33772705.
  • Parikh P, Jameel Z, Falcon S, Rosa M, Kiluk J, Hoover S, Soliman H, Ataya D. Adenomyoepithelioma of the breast: Case series and literature review. Clin Imaging. 2021 Jul.75:157-164. Pubmedid: 33607537.
  • Straker RJ, Song Y, Sun J, Shannon AB, Cohen LS, Muradova E, Daou H, Krause K, Li S, Frederick DT, Rhodin KE, Brizel DM, Boland GM, Beasley GM, Wuthrick EJ, Sondak VK, Zager JS, Lin A, Lukens JN, Karakousis GC. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul.28(7):3512-3521. Pubmedid: 33230747.
  • Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranisinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. 2021 Jul.128(1):65-71. Pubmedid: 33210440.
  • Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. 2021 Jul.80(1):1-3. Pubmedid: 32861573. Pmcid: PMC7448869.
  • Oswald LB, Arredondo B, Kadono M, Martinez-Tyson D, Meade CD, Penedo F, Antoni MH, Soliman H, Costa RLB, Jim HSL. A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers. Cancer Med. 2021 Jun. Pubmedid: 34165265.
  • Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Jun. Pubmedid: 34166502.
  • Tarhini AA, Joshi I, Garner F. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy. 2021 Jun. Pubmedid: 34157863.
  • Aoyama S, Nakagawa R, Nemoto S, Perez-Villarroel P, Mulé JJ, Mailloux AW. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135102. Pmcid: PMC8211075.
  • DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, Olivieri A, Pulanic D, Halter JP, Henderson LA, Zeiser R, Gooley TA, MacDonald KPA, Wolff D, Schultz KR, Paczesny S, Inamoto Y, Cutler CS, Kitko CL, Pidala JA, Lee SJ, Socie G, Sarantopoulos S, Pavletic SZ, Martin PJ, Blazar BR, Greinix HT. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther. 2021 Jun. Pubmedid: 34147469.
  • Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, Han D. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021 Jun. Pubmedid: 34120749.
  • Li R. Editorial Comment. J Urol. 2021 Jun. Pubmedid: 34121428.
  • Inamoto Y, Martin PJ, Onstad LE, Cheng GS, Williams KM, Pusic I, Ho VT, Arora M, Pidala J, Flowers MED, Gooley TA, Lawler RL, Hansen JA, Lee SJ. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: Plasma MMP-9 in BOS. Transplant Cell Ther. 2021 Jun. Pubmedid: 34126278.
  • Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S, Bhardwaj N. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021 Jun.39(6):725-729. Pubmedid: 34129817.
  • Van Vliet A, Girardot A, Bouchez J, Bigness A, Wang K, Moino D, Theodotou A, Pothuraju T, Felder S, Smith P, Kumar A, Dayicioglu D. How Big Is Too Big?: The Effect of Defect Size on Postoperative Complications of Vertical Rectus Abdominis Flap Reconstruction. Ann Plast Surg. 2021 Jun.86(6S Suppl 5):S571-S574. Pubmedid: 34100815.
  • Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med. 2021 Jun.19(1):238. Pubmedid: 34078406. Pmcid: PMC8173810.
  • Cornelius LA, Fields RC, Tarhini A. Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review. Oncologist. 2021 Jun. Pubmedid: 34080754.
  • McNiff KK, Caligiuri MA, Davidson NE, Farrar W, Fisher RI, Glimcher LH, Hanners RB, Hwu P, Johnson CS, Pisters PWT, Thompson CB, Reddy AS, Jagels B, Kolosky JA, Ross T, Bird K. Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers. Oncologist. 2021 Jun. Pubmedid: 34076924.
  • Jain AG, Talati C, Pinilla-Ibarz J. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia. Expert Opin Inv Drug. 2021 Jun.30(6):595-601. Pubmedid: 34053383.
  • Wilson CM, Li K, Sun Q, Kuan PF, Wang X. Fenchel duality of Cox partial likelihood with an application in survival kernel learning. Artif Intell Med. 2021 Jun.116:102077. Pubmedid: 34020756. Pmcid: PMC8159024.
  • de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021 Jun.54(6):1154-1167.e7. Pubmedid: 33979578. Pmcid: PMC8192496.
  • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun.39(18):1971-1982. Pubmedid: 33905264.
  • Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021 Jun.39(17):1888-1898. Pubmedid: 33877856. Pmcid: PMC8189612.
  • Williams KM, Inamoto Y, Im A, Hamilton B, Koreth J, Arora M, Pusic I, Mays JW, Carpenter PA, Luznik L, Reddy P, Ritz J, Greinix H, Paczesny S, Blazar BR, Pidala J, Cutler C, Wolff D, Schultz KR, Pavletic SZ, Lee SJ, Martin PJ, Socie G, Sarantopoulos S. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 Jun.27(6):452-466. Pubmedid: 33877965. Pmcid: PMC8217141.
  • Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021 Jun.161(3):693-699. Pubmedid: 33812698.
  • Christakopoulos GE, DeFor TE, Hage S, Wagner JE, Linden MA, Brunstein C, Bejanyan N, Verneris MR, Smith AR. Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation. Transplant Cell Ther. 2021 Jun.27(6):497.e1-497.e6. Pubmedid: 33785364. Pmcid: PMC8217114.
  • Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol. 2021 Jun.205(6):1620-1621. Pubmedid: 33734859.
  • Haydar D, Houke H, Chiang J, Yi Z, Odé Z, Caldwell K, Zhu X, Mercer KS, Stripay JL, Shaw TI, Vogel P, DeRenzo C, Baker SJ, Roussel MF, Gottschalk S, Krenciute G. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neurooncol. 2021 Jun.23(6):999-1011. Pubmedid: 33320196. Pmcid: PMC8168826.
  • Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun.17(17):2151-2167. Pubmedid: 33709791.
  • Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. J Urol. 2021 Jun.205(6):1612-1621. Pubmedid: 33502236.
  • Okoev G, Weisdorf DJ, Wagner JE, Blazar BR, MacMillan ML, DeFor T, Lazaryan A, El Jurdi N, Holtan SG, Brunstein CG, Betts BC, Takahashi T, Bachanova V, Warlick ED, Rashidi A, Arora M. Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. Bone Marrow Transplant. 2021 Jun.56(6):1373-1380. Pubmedid: 33420387.
  • Broman KK, Joyce D, Binitie O, Letson GD, Gonzalez RJ, Choi J, Mullinax JE. Intraoperative Localization Using an Implanted Radar Reflector Facilitates Resection of Non-Palpable Trunk and Extremity Sarcoma. Ann Surg Oncol. 2021 Jun.28(6):3366-3374. Pubmedid: 33073344.
  • Sun J, Henry DA, Carr MJ, Yazdankhahkenary A, Laronga C, Lee MC, Hoover SJ, Sun W, Czerniecki BJ, Khakpour N, Kiluk JV. Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. Clin Breast Cancer. 2021 Jun.21(3):e189-e193. Pubmedid: 32893094.
  • Powers BD, Felder SI, Imanirad I, Dessureault S, Dineen SP. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. J Gastrointest Cancer. 2021 Jun.52(2):719-727. Pubmedid: 32743731.
  • Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
  • Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 May. Pubmedid: 34077811.
  • Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan P, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021 May. Pubmedid: 34041526.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 May. Pubmedid: 34035069.
  • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Patterns of Recurrence Following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. J Urol. 2021 May. Pubmedid: 34032492.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 May. Pubmedid: 34032503.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
  • Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Ne. 2021 May.19(5):484-493. Pubmedid: 34030128.
  • Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 May.9(5). Pubmedid: 34021033. Pmcid: PMC8144048.
  • Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 May. Pubmedid: 34017072.
  • El Jurdi N, Elhusseini H, Beckman J, DeFor TE, Okoev G, Rogosheske J, Lazaryan A, Weiler K, Bachanova V, Betts BC, Blazar BR, Brunstein CG, He F, Holtan SG, Janakiram M, Gangaraju R, Maakaron J, MacMillan ML, Rashidi A, Warlick ED, Bhatia S, Vercellotti G, Weisdorf DJ, Arora M. High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer J. 2021 May.11(5):96. Pubmedid: 34006823. Pmcid: PMC8131386.
  • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2021 May. Pubmedid: 33994165.
  • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
  • Hyland KA, Nelson AM, Eisel SL, Hoogland AI, Ibarz-Pinilla J, Sweet K, Jacobsen PB, Knoop H, Jim HSL. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia: A Pilot Study. Ann Behav Med. 2021 May. Pubmedid: 33991085.
  • Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Dyrskjøt L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021 May. Pubmedid: 33975782.
  • Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 May.JCO2100612. Pubmedid: 33979178.
  • Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 May.9(5). Pubmedid: 33963015. Pmcid: PMC8108687.
  • Berglund A, Putney RM, Hamaidi I, Kim S. Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Exp Mol Med. 2021 May.53(5):761-771. Pubmedid: 33963293. Pmcid: PMC8178403.
  • Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 May.JCO2100079. Pubmedid: 33945288.
  • Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Tao J, Seto E, Pinilla-Ibarz J, Sotomayor EM. HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. J Leukoc Biol. 2021 May.109(5):891-900. Pubmedid: 33866588.
  • Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
  • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
  • Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett D, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunol Res. 2021 May.9(5):554-567. Pubmedid: 33653716. Pmcid: PMC8102376.
  • Mandula JK, Rodriguez PC. Tumor-related stress regulates functional plasticity of MDSCs. Cell Immunol. 2021 May.363:104312. Pubmedid: 33652258. Pmcid: PMC8026602.
  • Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May.94:107481. Pubmedid: 33636562. Pmcid: PMC8205103.
  • Bachmeier CA, Kurian TJ, Davila ML. Regulatory challenges and considerations for the clinical application of CAR T cell therapy. Expert Opin Biol Ther. 2021 May.21(5):549-552. Pubmedid: 33555927.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Chahoud J, Gleber-Netto FO, McCormick BZ, Rao P, Lu X, Guo M, Morgan MB, Chu RA, Martinez-Ferrer M, Eterovic AK, Pickering CR, Pettaway CA. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 May.27(9):2560-2570. Pubmedid: 33441293.
  • Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 May.27(10):2678-2697. Pubmedid: 33414132. Pmcid: PMC8127340.
  • Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner AJ, Pousa AL, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist. 2021 May.26(5):e863-e873. Pubmedid: 33289960. Pmcid: PMC8100574.
  • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
  • Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
  • Hagerty BL, Torres MB, Drake J, Hernandez JM, Mullinax JE, Blakely AM, Davis JL. Trends and Predictors of Failure of Minimally Invasive Surgery for Gastric GIST. J Gastrointest Surg. 2021 May.25(5):1319-1322. Pubmedid: 33057943.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Abou-Foul AK, Muzaffar J, Diakos E, Best JE, Momtahan N, Jayaram S. Correlation Between Thyroid Fine Needle Aspiration Cytology and Postoperative Histology: A 10-Year Single-Centre Experience. Cureus. 2021 Apr.13(4):e14504. Pubmedid: 34007757. Pmcid: PMC8123937.
  • Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol. 2021 Apr. Pubmedid: 33935020.
  • Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2021 Apr.11(4):82. Pubmedid: 33927193. Pmcid: PMC8085088.
  • Chin JL, Lavi A, Metcalfe MJ, Siddiqui K, Dewar M, Petros FG, Li R, Nogueras González GM, Wang X, Nair SM, Ward JF, Pisters L. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. J Urol. 2021 Apr.101097JU0000000000001831. Pubmedid: 33908799.
  • Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 Apr. Pubmedid: 33895402.
  • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2021 Apr. Pubmedid: 33900647.
  • Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics. 2021 Apr. Pubmedid: 33901274.
  • Straker RJ, Carr MJ, Sinnamon AJ, Shannon AB, Sun J, Landa K, Baecher KM, Wood C, Lynch K, Bartels HG, Panchaud R, Lowe MC, Slingluff CL, Jameson MJ, Tsai K, Faries MB, Beasley GM, Sondak V, Karakousis GC, Zager JS, Miura JT. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Ann Surg Oncol. 2021 Apr. Pubmedid: 33890195.
  • Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Johnson J, Fridley BL, List AF. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Adv. 2021 Apr.5(8):2216-2228. Pubmedid: 33890980. Pmcid: PMC8095151.
  • Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). Neurooncol. 2021 Apr. Pubmedid: 33880555.
  • Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 Apr.101097JU0000000000001788. Pubmedid: 33881933.
  • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
  • Drashansky TT, Helm EY, Curkovic N, Cooper J, Cheng P, Chen X, Gautam N, Meng L, Kwiatkowski AJ, Collins WO, Keselowsky BG, Sant'Angelo D, Huo Z, Zhang W, Zhou L, Avram D. BCL11B is positioned upstream of PLZF and RORγt to control thymic development of mucosal-associated invariant T cells and MAIT17 program. iScience. 2021 Apr.24(4):102307. Pubmedid: 33870128. Pmcid: PMC8042176.
  • Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Apr. Pubmedid: 33864019.
  • Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer. 2021 Apr.9(4). Pubmedid: 33849925. Pmcid: PMC8051418.
  • Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J. Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. Blood. 2021 Apr. Pubmedid: 33851211.
  • Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather M, van Houdt WJ, Stoeckle E, Park JB, Albertsmeier M, Nessim C, Cardona K, Fiore M, Hayes A, Tzanis D, Skoczylas J, Ford SJ, Ng D, Mullinax JE, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Stacchiotti S, Jones RL, DeLaney T, Roland CL, Raut CP, Gronchi A. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021 Apr. Pubmedid: 33852100.
  • Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 Apr.19(1):142. Pubmedid: 33827575. Pmcid: PMC8028182.
  • Ascierto PA, Brody J, Butterfield LH, Finn OJ, Goldberg J, Perrone F, Sullivan RJ, Fox BA, Hwu P, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. J Transl Med. 2021 Apr.19(1):144. Pubmedid: 33827609. Pmcid: PMC8025454.
  • Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021 Apr.118(15). Pubmedid: 33827917. Pmcid: PMC8053941.
  • Li Q, Wang X. Differential Expression Analysis of Long Noncoding RNAs. Methods Mol Biol. 2021 Apr.2284:193-205. Pubmedid: 33835444.
  • Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine JE, Ayuk F, Dignan F, Schoemans H, Tkaczyk E, Farhadfar N, Lawitschka A, Schultz KR, Martin PJ, Sarantopoulos S, Inamoto Y, Socie G, Wolff D, Blazar B, Greinix H, Paczesny S, Pavletic S, Hill G. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021 Apr. Pubmedid: 33836313.
  • Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 Apr.206(8):1966-1975. Pubmedid: 33722878. Pmcid: PMC8023145.
  • Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 Apr. Pubmedid: 33619985.
  • Peres LC, Townsend MK, Birmann BM, Conejo-Garcia JR, Kim Y, Kubzansky LD, Magpantay LI, Martínez-Maza O, Tworoger SS. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev. 2021 Apr.30(4):710-718. Pubmedid: 33563649.
  • Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G, Patel J, Bhargava V, Wilkinson P, Smirnov D, Sepulveda MA, Singhal S, Eruslanov EB, Cristescu R, Loboda A, Nefedova Y, Gabrilovich DI. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr.218(4). Pubmedid: 33566112. Pmcid: PMC7879582.
  • Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. ESMO Open. 2021 Apr.6(2):100050. Pubmedid: 33556898. Pmcid: PMC7872980.
  • Li R, Lerner SP, Kamat AM. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. Eur Urol. 2021 Apr.79(4):437-439. Pubmedid: 33454163.
  • Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 2021 Apr.127(8):1293-1300. Pubmedid: 33289918.
  • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
  • Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 Apr.137(13):1832-1835. Pubmedid: 33156925.
  • Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Forget MA, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu P. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immun. 2021 Apr.70(4):1101-1113. Pubmedid: 33123754. Pmcid: PMC7979613.
  • Tang CA, Lee AC, Chang S, Xu Q, Shao A, Lo Y, Spalek WT, Pinilla-Ibarz JA, Del Valle JR, Hu CA. STING regulates BCR signaling in normal and malignant B cells. Cell Mol Immunol. 2021 Apr.18(4):1016-1031. Pubmedid: 32999453. Pmcid: PMC8115116.
  • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST. A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors. J Genet Couns. 2021 Apr.30(2):394-405. Pubmedid: 32936981. Pmcid: PMC7960565.
  • Edgar RH, Tarhini A, Sander C, Sanders ME, Cook JL, Viator JA. Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry. Lasers Surg Med. 2021 Apr.53(4):578-586. Pubmedid: 32557708. Pmcid: PMC7746591.
  • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
  • Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021 Mar.7(2):373-380. Pubmedid: 31901438. Pmcid: PMC7771328.
  • Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
  • Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
  • Robinson LA, Fontaine J, El-Haddad G, Bryant S, Perez B, Toloza E, Kis B. Novel Subdiaphragmatic Ligation of Left Thoracic Duct for Refractory Postoperative Left Chylothorax. Ann Thorac Surg. 2021 Mar. Pubmedid: 33794166.
  • Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
  • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526.
  • Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. BJU Int. 2021 Mar. Pubmedid: 33783950.
  • Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 Mar. Pubmedid: 33770291.
  • Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux JM, Summitt IB, Bender JO, Young Kim J, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021 Mar. Pubmedid: 33753453.
  • Kimmel GJ, Locke FL, Altrock PM. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. Proc Biol Sci. 2021 Mar.288(1947):20210229. Pubmedid: 33757357. Pmcid: PMC8059581.
  • Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021 Mar.12(1):1717. Pubmedid: 33741967. Pmcid: PMC7979850.
  • Barata A, Hoogland AI, Hyland KA, Otto AK, Kommalapati A, Jayani RV, Irizarry-Arroyo N, Collier A, Rodriguez Y, Welniak TL, Booth-Jones M, Logue J, Small BJ, Jain MD, Reblin M, Locke FL, Jim HSL. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021 Mar. Pubmedid: 33739548.
  • Bandey IN, Adolacion JRT, Romain G, Paniagua MM, An X, Saeedi A, Liadi I, You Z, Rajanayake RB, Hwu P, Singh H, Cooper LJ, Varadarajan N. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling. J Immunother Cancer. 2021 Mar.9(3). Pubmedid: 33722906. Pmcid: PMC7970283.
  • Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
  • Wagner J, Wickman E, Shaw TI, Anido AA, Langfitt D, Zhang J, Porter SN, Pruett-Miller SM, Tillman H, Krenciute G, Gottschalk S. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin. Cancer Immunol Res. 2021 Mar.9(3):279-290. Pubmedid: 33355188. Pmcid: PMC7925432.
  • Shaw TI, Dong L, Tian L, Qian C, Liu Y, Ju B, High A, Kavdia K, Pagala VR, Shaner B, Pei D, Easton J, Janke LJ, Porter SN, Ma X, Cheng C, Pruett-Miller SM, Choi J, Yu J, Peng J, Gu W, Look AT, Downing JR, Zhang J. Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL). Sci Rep. 2021 Mar.11(1):5154. Pubmedid: 33664368. Pmcid: PMC7933146.
  • Holmes TD, Pandey RV, Helm EY, Schlums H, Han H, Campbell TM, Drashansky TT, Chiang S, Wu CY, Tao C, Shoukier M, Tolosa E, Von Hardenberg S, Sun M, Klemann C, Marsh RA, Lau CM, Lin Y, Sun JC, Månsson R, Cichocki F, Avram D, Bryceson YT. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci Immunol. 2021 Mar.6(57). Pubmedid: 33712472.
  • Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RH, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar. Pubmedid: 33707233.
  • Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer. 2021 Mar.7(1):26. Pubmedid: 33707440. Pmcid: PMC7952601.
  • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
  • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Mar. Pubmedid: 33658647.
  • Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: 33641257. Pmcid: PMC7957158.
  • Shields MD, Hicks JK, Boyle TA, Haura EB, Creelan BC. Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. J Thorac Oncol. 2021 Mar.16(3):e15-e17. Pubmedid: 33641722.
  • Shi LL, McMullen C, Vorwald K, Nichols AC, MacNeil SD, Wadsworth JT, Chung CH, Wang X, Patel KB. Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database. Eur Arch Otorhinolaryngol. 2021 Mar. Pubmedid: 33646344.
  • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
  • Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discov. 2021 Mar.11(3):560-574. Pubmedid: 33563662. Pmcid: PMC8193798.
  • Valisno JAC, May J, Singh K, Helm EY, Venegas L, Budbazar E, Goodman JB, Nicholson CJ, Avram D, Cohen RA, Mitchell GF, Morgan KG, Seta F. BCL11B Regulates Arterial Stiffness and Related Target Organ Damage. Circ Res. 2021 Mar.128(6):755-768. Pubmedid: 33530702. Pmcid: PMC7969164.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Innamarato P, Pilon-Thomas S. Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cell Immunol. 2021 Mar.361:104277. Pubmedid: 33476931. Pmcid: PMC7901256.
  • Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 Mar.31(2):160-169. Pubmedid: 33394766.
  • Chahoud J, Kohli M, Spiess PE. Management of Advanced Penile Cancer. Mayo Clin Proc. 2021 Mar.96(3):720-732. Pubmedid: 33308870.
  • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
  • Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, Pinilla-Ibarz J, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021 Mar.14(1):33-40. Pubmedid: 32473105. Pmcid: PMC7666647.
  • Bejanyan N, Vlasova-St Louis I, Mohei H, Cao Q, El Jurdi N, Wagner JE, Miller JS, Brunstein CG. Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation. Transplant Cell Ther. 2021 Feb.27(2):187.e1-187.e4. Pubmedid: 33718897. Pmcid: PMC7950718.
  • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
  • Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Feb. Pubmedid: 33775560.
  • Tarhini AA. Adjuvant Therapy of Melanoma. Hematol Oncol Clin North Am. 2021 Feb.35(1):73-84. Pubmedid: 33759774.
  • Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021 Feb.12(1):1281. Pubmedid: 33627663. Pmcid: PMC7904819.
  • Ramamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, Beyer A, Snyder C, Wiener D, Costa RLB, Czerniecki BJ. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Semin Cancer Biol. 2021 Feb. Pubmedid: 33626407.
  • Jonczyk MM, Fisher CS, Babbitt R, Paulus JK, Freund KM, Czerniecki B, Margenthaler JA, Losken A, Chatterjee A. Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator. Ann Surg Oncol. 2021 Feb. Pubmedid: 33616770.
  • Lazaryan A. New is forgotten old: IMiDs against chronic GVHD. Blood. 2021 Feb.137(7):862-864. Pubmedid: 33599761.
  • Muñoz NM, Williams M, Dixon K, Dupuis C, McWatters A, Avritscher R, Manrique SZ, McHugh K, Murthy R, Tam A, Naing A, Patel SP, Leach D, Hartgerink JD, Young S, Prakash P, Hwu P, Sheth RA. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J Immunother Cancer. 2021 Feb.9(2). Pubmedid: 33589526. Pmcid: PMC7887346.
  • Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 Feb.9(2). Pubmedid: 33589527. Pmcid: PMC7887353.
  • Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021 Feb.5(4):975-983. Pubmedid: 33576783. Pmcid: PMC7903230.
  • Hayes B, Brent J, Zhong Y, Bazmi S, Porta G, Bovbjerg DH, Tarhini A, Kirkwood JM, Brent DA, Marsland A, Melhem NM. Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth. J Clin Med. 2021 Feb.10(4). Pubmedid: 33557083. Pmcid: PMC7913784.
  • Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 Feb.27(2):301-309. Pubmedid: 33558722.
  • Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021 Feb. Pubmedid: 33526920. Pmcid: PMC7849958.
  • Bejanyan N, Anasetti C. First-line hypomethylating agents for patients with high risk chronic myelomonocytic leukaemia. Lancet Haematol. 2021 Feb.8(2):e99-e101. Pubmedid: 33513378.
  • Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Hensel J, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Feb.44(2):63-70. Pubmedid: 33443972. Pmcid: PMC8111686.
  • Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinogen. 2021 Feb.60(2):138-150. Pubmedid: 33378592. Pmcid: PMC7856233.
  • Soliman H, Hogue D, Han HS, Mooney B, Lima Barros Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H, Czerniecki BJ. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Feb.27(4):1012-1018. Pubmedid: 33219014.
  • Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 Feb.39(2):134.e9-134.e16. Pubmedid: 33187886.
  • Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2021 Feb.39(6):599-607. Pubmedid: 33125309.
  • Camacho-Bydume C, Wang T, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chharbra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplant Cell Ther. 2021 Feb.27(2):142.e1-142.e11. Pubmedid: 33053450. Pmcid: PMC8015676.
  • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543.
  • Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
  • Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol. 2021 Feb.28(2):1007-1016. Pubmedid: 32524460.
  • Aoyama S, Nakagawa R, Mulé JJ, Mailloux AW. Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy. Front Immunol. 2021 May.12:675538. Pubmedid: 34054863. Pmcid: PMC8160316.
  • Dibs K, Sim AJ, Peñagaricano JA, Latifi K, Garcia GA, Peters JA, Nieder ML, Kim S, Robinson TJ. Gonadal-sparing total body irradiation with the use of helical tomotherapy for nonmalignant indications. Rep Pract Oncol Radiother. 2021 Feb.26(1):153-158. Pubmedid: 34046227. Pmcid: PMC8149136.
  • Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol. 2021 May.12:669474. Pubmedid: 34012451. Pmcid: PMC8126720.
  • Ghimirey N, Steele C, Czerniecki BJ, Koski GK, Showalter LE. Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer. Int J Breast Cancer. 2021 Apr.2021:8818393. Pubmedid: 33936816. Pmcid: PMC8062178.
  • Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021 Feb.12:628063. Pubmedid: 33717150. Pmcid: PMC7949015.
  • Zekan DS, Dahman A, Hajiran AJ, Luchey AM, Chahoud J, Spiess PE. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol. 2021 Jan.47. Pubmedid: 33650835.
  • Wilson CM, Fridley BL, Conejo-Garcia JR, Wang X, Yu X. Wide and deep learning for automatic cell type identification. Comput Struct Biotechnol J. 2021 Jan.19:1052-1062. Pubmedid: 33613870. Pmcid: PMC7878986.
  • Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C. Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar. Front Immunol. 2021 Jan.11:589381. Pubmedid: 33584653. Pmcid: PMC7874217.
  • Law V, Baldwin M, Ramamoorthi G, Kodumudi K, Tran N, Smalley I, Duckett D, Kalinski P, Czerniecki B, Smalley KSM, Forsyth PA. A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. J Vis Exp. 2021 Jan.(167). Pubmedid: 33586709.
  • Elmariah H, Brunstein CG, Bejanyan N. Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. Life (Basel). 2021 Jan.11(2). Pubmedid: 33572932. Pmcid: PMC7911120.
  • Trizzino M, Zucco A, Deliard S, Wang F, Barbieri E, Veglia F, Gabrilovich D, Gardini A. EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. Sci Adv. 2021 Jan.7(3). Pubmedid: 33523892. Pmcid: PMC7806227.
  • Dalton R, Calescibetta A, Zhou JM, Maurin M, Ward G, Trinh TL, Tu N, Gilvary D, Chen X, Cheng P, Kostenko E, Wei S, Wright KL, Eksioglu EA. Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC. Int J Mol Sci. 2021 Jan.22(3). Pubmedid: 33513928. Pmcid: PMC7865632.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 Jan. Pubmedid: 33484074.
  • Kumar J, Kumar R, Kumar Singh A, Tsakem EL, Kathania M, Riese MJ, Theiss AL, Davila ML, Venuprasad K. Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 2021 Jan.9(1). Pubmedid: 33462140. Pmcid: PMC7813298.
  • Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest. 2021 Jan.131(2). Pubmedid: 33463538. Pmcid: PMC7810492.
  • Khunger A, Sarikonda G, Tsau J, Pahuja A, Alfonso Z, Gao J, Laing C, Vaupel C, Dakappagari N, Tarhini AA. Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma. Transl Oncol. 2021 Mar.14(3):101014. Pubmedid: 33450703. Pmcid: PMC7810775.
  • Khunger A, Piazza E, Warren S, Smith TH, Ren X, White A, Elliott N, Cesano A, Beechem JM, Kirkwood JM, Tarhini AA. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021 Jan.16(1):e0245287. Pubmedid: 33428680. Pmcid: PMC7799833.
  • Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 2021 Jan.151:30-38. Pubmedid: 33285469.
  • Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021 Jan.22(1):53-66. Pubmedid: 33230330.
  • Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Cancer Immunol Res. 2021 Jan.9(1):62-74. Pubmedid: 33188139. Pmcid: PMC7864379.
  • Watters JM, Wright G, Smith MA, Shah B, Wright KL. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochem Bioph Res Co. 2021 Jan.534:773-779. Pubmedid: 33190829. Pmcid: PMC7785659.
  • Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan.7(1):42-50. Pubmedid: 33180106. Pmcid: PMC7662490.
  • Mariotti V, Han H, Ismail-Khan R, Tang SC, Dillon P, Montero AJ, Poklepovic A, Melin S, Ibrahim NK, Kennedy E, Vahanian N, Link C, Tennant L, Schuster S, Smith C, Danciu O, Gilman P, Soliman H. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Jan.7(1):61-69. Pubmedid: 33151286. Pmcid: PMC7645745.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
  • El Jurdi N, Rogosheske J, DeFor T, Bejanyan N, Arora M, Bachanova V, Betts B, He F, Holtan S, Janakiram M, Larson S, Maakaron J, Rashidi A, Warlick E, Wagner JE, Young JH, Weisdorf D, Brunstein CG. Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Transplant Cell Ther. 2021 Jan.27(1):84.e1-84.e5. Pubmedid: 33053448.
  • Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
  • Creelan BC, Yeh TC, Kim SW, Nogami N, Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. Brit J Cancer. 2021 Jan.124(2):383-390. Pubmedid: 33012782. Pmcid: PMC7852511.
  • Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier B, Litzow M, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Ma. Transplant Cell Ther. 2021 Jan.27(1):68.e1-68.e9. Pubmedid: 33010430. Pmcid: PMC8015679.
  • Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, Giuliano AR, Schell MJ, Waterboer T, Pawlita M, McKay-Chopin S, Gheit T, Tommasino M, Rollison DE. Cutaneous viral infections associated with ultraviolet radiation exposure. Int J Cancer. 2021 Jan.148(2):448-458. Pubmedid: 32818302. Pmcid: PMC7754468.
  • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
  • Ketcher DE, Bidelman A, Le LQ, Otto AK, Lester DK, Amtmann-Beuttner KK, Gonzalez B, Wright KL, Vadaparampil ST, Reblin M, Lau EK. Partnering patients, caregivers, and basic scientists: an engagement model that fosters patient- and family-centered research culture. Transl Res. 2021 Jan.227:64-74. Pubmedid: 32739418. Pmcid: PMC7719089.
  • De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells. 2020 Dec.10(1). Pubmedid: 33374253. Pmcid: PMC7824606.
  • Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: 33335028. Pmcid: PMC7745688.
  • Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020 Dec.3(1):784. Pubmedid: 33335285. Pmcid: PMC7746703.
  • Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: 33310772. Pmcid: PMC7735083.
  • Tometich DB, Hyland KA, Soliman H, Jim HSL, Oswald L. Living with Metastatic Cancer: A Roadmap for Future Research. Cancers (Basel). 2020 Dec.12(12). Pubmedid: 33302472. Pmcid: PMC7763639.
  • Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: 33303579. Pmcid: PMC7733200.
  • Harro CM, Perez-Sanz J, Costich TL, Payne KK, Anadon Galindo CM, Chaurio RA, Biswas S, Mandal G, Rigolizzo KE, Sprenger KB, Mine JA, Showe L, Yu X, Liu K, Rodriguez PC, Pinilla-Ibarz J, Sokol L, Conejo-Garcia JR. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. J Clin Invest. 2020 Dec.131(3). Pubmedid: 33270606. Pmcid: PMC7843215.
  • Turner JG, Cui Y, Bauer AA, Dawson JL, Gomez JA, Kim J, Cubitt CL, Nishihori T, Dalton WS, Sullivan DM. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. Cancer Res. 2020 Dec.80(23):5344-5354. Pubmedid: 33023948. Pmcid: PMC7718436.
  • Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". Biol Blood Marrow Tr. 2020 Dec.26(12):e335-e336. Pubmedid: 32950694.
  • Mishra A, Bigam KD, Extermann M, Faramand R, Thomas K, Pidala JA, Baracos VE. Sarcopenia and low muscle radiodensity associate with impaired FEV1 in allogeneic haematopoietic stem cell transplant recipients. J Cachexia Sarcopenia Muscle. 2020 Dec.11(6):1570-1579. Pubmedid: 32729255. Pmcid: PMC7749567.
  • Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol. 2020 Dec.27(13):4883-4891. Pubmedid: 32318945.
  • Sondak VK, Messina JL, Tarhini AA. Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. J Am Coll Surg. 2020 Nov.231(5):554-556. Pubmedid: 33491653.
  • Sondak V. The use of molecular testing at a diagnosis of melanoma. Clin Adv Hematol Oncol. 2020 Nov.18(11):700-702. Pubmedid: 33406061.
  • Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Front Immunol. 2020 Nov.11:590072. Pubmedid: 33329575. Pmcid: PMC7719839.
  • Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Front Immunol. 2020 Nov.11:604142. Pubmedid: 33329600. Pmcid: PMC7734315.
  • Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 Nov.9(1):1847846. Pubmedid: 33312760. Pmcid: PMC7714520.
  • Lu H, Kim J, Qi J, Li Q, Liu Y, Schabath MB, Ye Z, Gillies RJ, Balagurunathan Y. Multi-Window CT Based Radiological Traits for Improving Early Detection in Lung Cancer Screening. Cancer Manag Res. 2020 Nov.12:12225-12238. Pubmedid: 33273859. Pmcid: PMC7707434.
  • Bharucha J, Cao Q, Sachs Z, Smith A, Williams S, Amin K, Bachanova V, Warlick E, Brunstein C, Weisdorf D, Bejanyan N. Prognostic factors for clinical outcomes of patients with central nervous system leukemia. Hematol Oncol Stem Cell Ther. 2020 Nov. Pubmedid: 33271117.
  • Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel). 2020 Nov.12(12). Pubmedid: 33255891. Pmcid: PMC7768436.
  • Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov.8(2). Pubmedid: 33199512. Pmcid: PMC7670953.
  • Qin Y, Bollin K, de Macedo MP, Carapeto F, Kim KB, Roszik J, Wani KM, Reuben A, Reddy ST, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Lazar AJ, Hwu P, Patel SP. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer. 2020 Nov.8(2). Pubmedid: 33203661. Pmcid: PMC7674090.
  • Perkins RM, Markowitz J. Correction to: Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center. Methods Mol Biol. 2020 Nov.2194:C1. Pubmedid: 33169350.
  • Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov.4(21):5414-5424. Pubmedid: 33147337. Pmcid: PMC7656920.
  • Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov.205(10):2893-2904. Pubmedid: 33020146. Pmcid: PMC7741883.
  • Gerhardt CA, Belzarena AC, Henderson-Jackson E, Mullinax JE, Joyce DM. Intrapelvic melanocytic schwannoma resection with computer-assisted navigation. Radiol Case Rep. 2020 Nov.15(11):2385-2390. Pubmedid: 32994847. Pmcid: PMC7516168.
  • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
  • Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, Conejo-Garcia JR, Hurez V, Gupta H, Curiel TJ. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020 Nov.80(22):5063-5075. Pubmedid: 32948605. Pmcid: PMC7669742.
  • Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 Nov.38(33):3863-3873. Pubmedid: 32910710. Pmcid: PMC7676888.
  • DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Tr. 2020 Nov.26(11):2075-2081. Pubmedid: 32818556.
  • Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov.31(11):1449-1461. Pubmedid: 32763452.
  • Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov.31(11):1435-1448. Pubmedid: 32763453.
  • Reljic T, Sehovic M, Lancet J, Kim J, Al Ali N, Djulbegovic B, Extermann M. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. Geriatr Oncol. 2020 Nov.11(8):1293-1308. Pubmedid: 32665186. Pmcid: PMC7864384.
  • Kubi B, Gunn J, Fackche N, Cloyd JM, Abdel-Misih S, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Patel SH, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Wang NY, Greer JB. Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J Surg Res. 2020 Nov.255:475-485. Pubmedid: 32622162.
  • Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl B, Kim M, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020 Nov.136(20):2308-2318. Pubmedid: 32614951. Pmcid: PMC7702478.
  • Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 Nov.38(33):3947-3970. Pubmedid: 32228358.
  • Bejanyan N, Rogosheske J, Cao Q, Lazaryan A, Holton S, Ustun C, Jacobson P, MacMillan M, Weisdorf DJ, Wagner J, Arora M, Brunstein CG. Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. Eur J Haematol. 2021 Feb.106(2):205-212. Pubmedid: 33084139.
  • Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 Oct.11(1):5332. Pubmedid: 33087697. Pmcid: PMC7577998.
  • Ahmed ME, Falasiri S, Hajiran A, Chahoud J, Spiess PE. The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. J Clin Med. 2020 Oct.9(10). Pubmedid: 33080912. Pmcid: PMC7603091.
  • Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lee B, Blakely A, Greer J, Johnston FM, Laskowitz D, Dessureault S, Dineen SP. CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Oct.27(13):4996-5004. Pubmedid: 33073341.
  • Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2020 Oct.38(4):585-590. Pubmedid: 33049209.
  • Leiting JL, Day CN, Harmsen WS, Cloyd JM, Abdel-Misih S, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapongh J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Morris MC, Hendrix RJ, Lambert LA, Abbott DE, Pokrzywa C, Raoof M, Eng O, Johnston FM, Greer J, Grotz TE. The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. Int J Hyperthermia. 2020 Oct.37(1):1182-1188. Pubmedid: 33040617.
  • Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik AA. Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma. J Immunother. 2021 Feb.44(2):86-89. Pubmedid: 33044384.
  • Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, Estecio MR, Barsoumian HB, Menon H, da Silva Caetano M, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW. Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 Oct.11(1):5144. Pubmedid: 33033261. Pmcid: PMC7546718.
  • Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Oct.4(19):4898-4911. Pubmedid: 33035333. Pmcid: PMC7556133.
  • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
  • Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, Wiener D, Beatty M, Nagle L, Creelan BC, Sarnaik AA, Pilon-Thomas S. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Mol Ther. 2020 Oct.28(10):2252-2270. Pubmedid: 32615068. Pmcid: PMC7544980.
  • Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. 2020 Oct.38(10):796.e1-796.e6. Pubmedid: 32430255.
  • Schipper J, Westerhuis JJ, Beddows I, Madaj Z, Monsma D, Hostetter G, Kiupel M, Conejo-Garcia JR, Sempere LF. Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. Int J Cancer. 2020 Oct.147(8):2265-2278. Pubmedid: 32388866.
  • Saglam O, Zhou J, Wang X, Conejo-Garcia JR. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. Int J Gynecol Pathol. 2020 Sep.39(5):428-435. Pubmedid: 31274701. Pmcid: PMC7010346.
  • Song J, Liu K, Pinilla-Ibarz J, Zhang H. A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation. Leuk Res Rep. 2020 Sep.14:100222. Pubmedid: 33072512. Pmcid: PMC7549112.
  • Zhang L, Kim S, Ren X. The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?. Front Oncol. 2020 Sep.10:1721. Pubmedid: 33014852. Pmcid: PMC7506103.
  • Paredes J, Zabaleta J, Garai J, Ji P, Imtiaz S, Spagnardi M, Alvarado J, Li L, Akadri M, Barrera K, Munoz-Sagastibelza M, Gupta R, Alshal M, Agaronov M, Talus H, Wang X, Carethers JM, Williams JL, Martello LA. Immune-Related Gene Expression and Cytokine Secretion Is Reduced Among African American Colon Cancer Patients. Front Oncol. 2020 Sep.10:1498. Pubmedid: 32983990. Pmcid: PMC7492388.
  • Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes A, Lu Y, Estecio MR, Barsoumian HB, Menon H, Caetano MDS, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 Sep.11(1):4840. Pubmedid: 32973129. Pmcid: PMC7519103.
  • Tarhini AA. The current state of adjuvant therapy of melanoma. Lancet Oncol. 2020 Nov.21(11):1394-1395. Pubmedid: 32961120.
  • Chahoud J, Tamil M, Necchi A. Second line salvage systemic therapy for advanced penile cancer. Urol Oncol. 2020 Sep. Pubmedid: 32950396.
  • Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2020 Sep. Pubmedid: 32936333. Pmcid: PMC8101019.
  • Perkins RM, Markowitz J. Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center. Methods Mol Biol. 2020 Sep.2194:1-19. Pubmedid: 32926358.
  • Lin TA, Eroglu Z, Carvajal R, Markowitz J. Cohort Identification for Translational Bioinformatics Studies. Methods Mol Biol. 2020 Sep.2194:35-44. Pubmedid: 32926360. Pmcid: PMC7787345.
  • Yu X, Abbas-Aghababazadeh F, Chen YA, Fridley BL. Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments. Methods Mol Biol. 2020 Sep.2194:143-175. Pubmedid: 32926366. Pmcid: PMC7771369.
  • Sun J, Kroeger JL, Markowitz J. Introduction to Multiparametric Flow Cytometry and Analysis of High-Dimensional Data. Methods Mol Biol. 2020 Sep.2194:239-253. Pubmedid: 32926370. Pmcid: PMC7868168.
  • Nakagawa R, Brayer J, Restrepo N, Mulé JJ, Mailloux AW. High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells. Methods Mol Biol. 2020 Sep.2194:255-290. Pubmedid: 32926371. Pmcid: PMC7744271.
  • Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 Sep.18(1):346. Pubmedid: 32894202. Pmcid: PMC7487701.
  • Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Sep.21(9):1188-1200. Pubmedid: 32888452.
  • Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
  • Wei WZ, Gibson HM, Jacob JB, Frelinger JA, Berzofsky JA, Maeng H, Dyson G, Reyes JD, Pilon-Thomas S, Ratner S, Wei KC. Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. J Immunol. 2020 Sep.205(6):1554-1563. Pubmedid: 32796024. Pmcid: PMC7484363.
  • Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metab. 2020 Sep.32(3):420-436.e12. Pubmedid: 32768387. Pmcid: PMC7484212.
  • Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 Sep.156(9):1004-1011. Pubmedid: 32725204.
  • Karakousis G, Sondak VK, Zager JS. Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. J Clin Oncol. 2020 Sep.38(27):3234-3235. Pubmedid: 32701416.
  • Locke FL. Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. Biol Blood Marrow Tr. 2020 Sep.26(9):e211-e212. Pubmedid: 32682950.
  • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
  • Krzyston H, Morse B, Deperalta D, Rishi A, Kayaleh R, El-Haddad G, Smith J, Druta M, Kis B. Liver-directed treatments of liver-dominant metastatic leiomyosarcoma. Diagn Interv Radiol. 2020 Sep.26(5):449-455. Pubmedid: 32673206. Pmcid: PMC7490031.
  • Wang X, Yu X, Krauthammer M, Hugo W, Duan C, Kanetsky PA, Teer JK, Thompson ZJ, Kalos D, Tsai KY, Smalley KSM, Sondak VK, Chen YA, Conejo-Garcia JR. The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. 2020 Sep.29(9):1792-1799. Pubmedid: 32611582. Pmcid: PMC7483810.
  • Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Tr. 2020 Sep.26(9):1581-1588. Pubmedid: 32561336.
  • Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh AR, Jain R, Carrizosa DR, Soliman H, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 Sep.26(18):4814-4822. Pubmedid: 32554514.
  • Pidala J, Bhatt VR, Hamilton B, Pusic I, Wood WA, Onstad L, Hall A, Storer B, Lee SJ. Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. Biol Blood Marrow Tr. 2020 Sep.26(9):1612-1619. Pubmedid: 32464285.
  • Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Li G, Ghafoor T, Felices M, Miller J, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. J Clin Invest. 2020 Sep.130(9):4652-4662. Pubmedid: 32437331. Pmcid: PMC7456225.
  • Barata A, Gonzalez BD, Zhou JM, Kim J, Hoogland AI, El-Jawahri A, Booth-Jones M, Jim HSL. Associations among depression, antidepressants, survival and quality of life in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2020 Sep.55(9):1868-1871. Pubmedid: 32398786. Pmcid: PMC7968382.
  • Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep.38(27):3119-3128. Pubmedid: 32401634. Pmcid: PMC7499611.
  • Jiang C, Wallington DG, Anker CJ, Lawson DH, Yushak ML, Kudchadkar RR, Tarhini A, Khan MK. Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery. 2020 Sep.87(3):498-515. Pubmedid: 32315430.
  • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
  • Goyal A, O'Leary D, Goyal K, Rubin N, Bohjanen K, Hordinsky M, Chen ST, Pongas G, Duncan LM, Lazaryan A. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol. 2020 Aug.83(2):404-411. Pubmedid: 31374302. Pmcid: PMC7021276.
  • Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Brit J Haematol. 2020 Aug.190(4):573-582. Pubmedid: 32314807. Pmcid: PMC7575614.
  • Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Tr. 2020 Aug.26(8):1459-1468. Pubmedid: 32434056. Pmcid: PMC7391266.
  • Gonzalez R, Pidala J. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. Pharmacotherapy. 2020 Aug.40(8):756-772. Pubmedid: 32441379.
  • Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB, Kim DW. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020 Aug.126(15):3464-3470. Pubmedid: 32453456. Pmcid: PMC7787270.
  • Brohl AS, Sondak VK. Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. J Clin Oncol. 2020 Aug.38(22):2471-2475. Pubmedid: 32530767.
  • Wu RC, Newman W, Patanowitz L, Branstetter BF, Amankulor N, Tarhini AA. Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy. 2020 Aug.12(11):763-769. Pubmedid: 32571131. Pmcid: PMC7421879.
  • Ugolini A, Tyurin V, Tyurina Y, Tsyganov E, Donthireddy L, Kagan VE, Gabrilovich DI, Veglia F. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. 2020 Aug.5(15). Pubmedid: 32584791. Pmcid: PMC7455061.
  • Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020 Aug.6(8):1256-1264. Pubmedid: 32672795. Pmcid: PMC7366279.
  • Bakhshwin A, Berry RS, Cox RM, Li R, Reynolds JP, Rubin BP, McKenney JK. Malignant solitary fibrous tumour of the prostate: four cases emphasising significant histological and immunophenotypical overlap with sarcomatoid carcinoma. Pathology. 2020 Oct.52(6):643-648. Pubmedid: 32758370.
  • Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Ibrahim-Hashim A, Longo DL, Reshetnyak YK, Moshnikova A, Andreev OA, Luddy K, Damaghi M, Kodumudi K, Pillai SR, Enriquez-Navas P, Pilon-Thomas S, Swietach P, Gillies RJ. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat Commun. 2020 Aug.11(1):4113. Pubmedid: 32807791. Pmcid: PMC7431837.
  • Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 Oct.17(10):555-570. Pubmedid: 32812000.
  • Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020 Aug.369(6506):942-949. Pubmedid: 32820120. Pmcid: PMC7646930.
  • Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020 Aug.10(8):1158-1173. Pubmedid: 32439653.
  • Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immun. 2020 Aug.69(8):1519-1534. Pubmedid: 32300858. Pmcid: PMC7997043.
  • Damgaci S, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ, Ibrahim-Hashim A. Immunotherapy on acid: opportunities and challenges. Eur J Clin Nutr. 2020 Aug.74(Suppl 1):3-6. Pubmedid: 32873950. Pmcid: PMC7777416.